Work

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.7526

Authors: Gurdeep Parmar, Marcelo Capra, Fernanda Seguro, Vania Hungria, Meletios Athanasios Dimopoulos, Sosana Delimpasi, Jiri Minarik, Ludek Pour, Graca Esteves, Kazutaka Sunami, Junichiro Yuda, Ivan Spicka, Roman Hajek, Christine Soufflet, Disa Yu, Victorine Koch, Florence Suzan, Hang Quach

Institutions: Hospital Mãe de Deus, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Germano Oncologia, National and Kapodistrian University of Athens, Evangelismos Hospital, University Hospital Olomouc, Palacký University Olomouc, University Hospital Brno, Hospital de Santa Maria, Okayama Medical Center, National Cancer Center Hospital East, Charles University, General University Hospital in Prague, University of Ostrava, University Hospital Ostrava, Sanofi (France), Sanofi (United States), The University of Melbourne, St Vincent's Hospital Melbourne

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809897

Cites:

Cited by: 2

Related to: 10